A randomized controlled study on the treatment of lupus nephritis

INTERVENTION: A:MMF 0.75 1.0g/d in induction stage, MMF0.5 0.75g/d in maintenance stage ;B:FK506 0.1mg/kg/d in induction stage, FK506 0.05mg/kg/d in maintenance stage ;C:Intravenous CYC was given in monthly pulses of 0.5‐0.75g/m2 in induction stage, Aza 1‐2mg/kg/d in maintenance stage; CONDITION: Active lupus nephritis PRIMARY OUTCOME: Complete remission rate; INCLUSION CRITERIA: 1. Patients who aged 18 to 65 years and had a diagnosis of systemic lupus erythematosus, as defined by the 1997 revised American Rheumatism Association criteria; 2. Renal biopsy showing active lupus nephritis (classes III, IV‐S or IV‐G, V, III+V, or IV+V according to the 2003 International Society of Nephrology/Renal Pathology Society classification); 3. urinary protein excretion of 1.0 g/24 h or above; 4. With informed consent signed.